First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.

ABSTRACT:

Background

The phase 3 KEYNOTE-590 (NCT03189719) study showed first-line pembrolizumab plus chemotherapy significantly prolonged overall survival and progression-free survival versus placebo plus chemotherapy in patients with advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction. We describe a subgroup analysis of Japanese patients from KEYNOTE-590.

Methods

Eligible patients were randomly assigned 1:1 to pembrolizumab 200 mg intravenously every 3 weeks or placebo plus chemotherapy (cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day). Efficacy was evaluated in all Japanese patients and those with esophageal squamous cell carcinom

SUBMITTER: Kojima T 

PROVIDER: S-EPMC9436840 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature